2023年肝细胞癌多学科治疗:意大利肝脏研究学会(AISF)等11家学会联合实践治疗指南——第二部分——非手术治疗
全文未报告具体推荐条款、证据等级及影像学诊断数值。
要点
- 原文未报告具体的非手术治疗推荐条款、推荐强度或证据等级。
- 原文未报告影像学诊断标准、敏感度、特异度或阈值等数值。
核心结论
- 指南旨在为肝细胞癌的多学科治疗管理提供基于证据的更新推荐,第二部分聚焦多学科肿瘤专家委员会与非手术治疗。
临床应用与阅片要点
- 原文未据此给出具体的临床操作推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Worldwide, hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death. The remarkable improvements in treating HCC achieved in the last years have increased the complexity of its management. Following the need to have updated guidelines on the multidisciplinary treatment management of HCC, the Italian Scientific Societies involved in the management of this cancer have promoted the drafting of a new dedicated document. This document was drawn up according to the GRADE methodology needed to produce guidelines based on evidence. Here is presented the second part of guidelines, focused on the multidisciplinary tumor board of experts and non-surgical treatments of HCC.
引用
- Cabibbo G, Daniele B, Borzio M, et al. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) - Part II - Non-surgical treatments. Dig Liver Dis. 2023. PMID: 38052656. doi:10.1016/j.dld.2023.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。